In yesterday’s Wall Street session, CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded at $67.89, up 14.64% from the previous session.
28 analysts cover CRISPR Therapeutics AG (NASDAQ:CRSP), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $220.00 and a low of $42.00, we find $80.00. Given the previous closing price of $59.22, this indicates a potential upside of 35.09 percent. CRSP stock price is now 46.02% away from the 50-day moving average and 31.69% away from the 200-day moving average. The market capitalization of the company currently stands at $5.39B.
The stock has received a hold rating from 11 analysts and a buy rating from 15. Brokers who have rated the stock have averaged $87.78 as their price target over the next twelve months.
In other news, Kulkarni Samarth, Chief Executive Officer sold 25,000 shares of the company’s stock on May 30. The stock was sold for $1,621,894 at an average price of $64.88. Upon completion of the transaction, the Chief Executive Officer now directly owns 387,377 shares in the company, valued at $26.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 25, Chief Executive Officer Kulkarni Samarth sold 25,000 shares of the business’s stock. A total of $1,266,638 was realized by selling the stock at an average price of $50.67. This leaves the insider owning 387,377 shares of the company worth $26.3 million. Insiders disposed of 221,626 shares of company stock worth roughly $15.05 million over the past 1 year. A total of 4.00% of the company’s stock is owned by insiders.
On Friday morning CRISPR Therapeutics AG (NASDAQ: CRSP) stock kicked off with the opening price of $61.18. During the past 12 months, CRISPR Therapeutics AG has had a low of $37.55 and a high of $72.00. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 15.83, and a quick ratio of 15.83. The fifty day moving average price for CRSP is $46.64 and a two-hundred day moving average price translates $51.55 for the stock.
The latest earnings results from CRISPR Therapeutics AG (NASDAQ: CRSP) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$1.41, beating analysts’ expectations of -$1.95 by 0.54. This compares to -$2.24 EPS in the same period last year. The net profit margin was -207.95% and return on equity was -19.20% for CRSP. For the current quarter, analysts expect CRSP to generate $113.31M in revenue.
CRISPR Therapeutics AG(CRSP) Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.